Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...
Data Insights
CAN-3110 by Candel Therapeutics for Recurrent Malignant Glioma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for Recurrent Malignant Glioma. According to GlobalData,...